Skip to main content

Regencell Bioscience Holdings Ltd

RGC
Exchange
Nasdaq
Industry
Medicinal Chemicals & Botanical Products
SEC CIK
0001829667

No open-market purchases or sales by Regencell Bioscience Holdings Ltd insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q2 2026, worth $8.56M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Regencell Bioscience Holdings Ltd changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of RGC: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders3120
Shares56323818.1K+17.8K (+5,473.5%)
Value$1.89K$800$100.4K+$99.3K (+9,098.0%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (1)

Institutions that held Regencell Bioscience Holdings Ltd at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to RGC in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.238$1.32K0.00%

Sold out (1)

Institutions that held Regencell Bioscience Holdings Ltd at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of RGC in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Qube Research & Technologies Ltd13$44

Not filed for Q3 2024 yet (1)

Institutions that held Regencell Bioscience Holdings Ltd at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding RGC in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.238$800